{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:53:37Z","timestamp":1791273217005,"version":"4.1.0"},"reference-count":210,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lungcan.2026.109518","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:45:55Z","timestamp":1783352755000},"page":"109518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nanoparticle-based drug delivery for precision lung cancer therapy: Tumor microenvironment modulation and theranostic applications"],"prefix":"10.1016","volume":"219","author":[{"given":"Ramaraj Rajesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8489-531X","authenticated-orcid":false,"given":"Israel VMV","family":"Enoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0005","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA: Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0010","doi-asserted-by":"crossref","first-page":"6214","DOI":"10.18632\/aging.202504","article-title":"Early diagnosis of lung cancer: which is the optimal choice?","volume":"13","author":"Ning","year":"2021","journal-title":"Aging"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/aort.aort_11_24","article-title":"Clinicopathological profile of the patients with lung cancer at a tertiary care institute from South India","volume":"4","author":"Reddy","year":"2024","journal-title":"Anna. Oncol. Res. Therapy"},{"key":"10.1016\/j.lungcan.2026.109518_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.960317","article-title":"Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action","volume":"12","author":"Tilsed","year":"2022","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0025","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11864-024-01257-6","article-title":"Management of pulmonary toxicities associated with systemic therapy in non small cell lung cancer","volume":"25","author":"Velimirovic","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0030","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/ph14100970","article-title":"Anticancer drug-induced cardiotoxicity: insights and pharmacogenetics","volume":"14","author":"Adhikari","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lungcan.2026.109518_b0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signaling"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","article-title":"Targeted drug delivery strategies for precision medicines","volume":"6","author":"Manzari","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.lungcan.2026.109518_b0045","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1039\/D5PM00137D","article-title":"Recent advances in biomedical applications of smart nanomaterials: a comprehensive review","volume":"2","author":"Goshisht","year":"2025","journal-title":"RSC Pharm."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109518_b0050","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/pharmaceutics16030332","article-title":"Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare","volume":"16","author":"Marques","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/mr-2023-0058","article-title":"Nanotechnology-based delivery systems to overcome drug resistance in cancer","volume":"4","author":"Patel","year":"2024","journal-title":"Med. Rev."},{"key":"10.1016\/j.lungcan.2026.109518_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125789","article-title":"Artificial intelligence revolution in drug discovery: a paradigm shift in pharmaceutical innovation","volume":"680","author":"Jarallah","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109518_b0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/jpm12050673","article-title":"The promise of nanotechnology in personalized medicine","volume":"12","author":"Alghamdi","year":"2022","journal-title":"J. Personal. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109518_b0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4155\/tde-2023-0020","article-title":"Nano-drug delivery system: a promising approach against breast cancer","volume":"14","author":"Malik","year":"2023","journal-title":"Ther. Deliv."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109518_b0075","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/cancers14030622","article-title":"Targeted delivery methods for anticancer drugs","volume":"14","author":"Veselov","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109518_b0080","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/pharmaceutics13060770","article-title":"Degradation of drug delivery nanocarriers and payload release: a review of physical methods for tracing nanocarrier biological fate","volume":"13","author":"Perrigue","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lungcan.2026.109518_b0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s43939-026-00542-5","article-title":"Nanonizing bioactives: precision chemistry for next-gen therapeutics","volume":"6","author":"Biswas","year":"2026","journal-title":"Discover Mater."},{"key":"10.1016\/j.lungcan.2026.109518_b0090","article-title":"Enhancement of the efficacy of synthetic and natural anticancer agents through nanocarrier for colon cancer treatment","volume":"10","author":"Mukherjee","year":"2024","journal-title":"Eur. J. Med. Chem. Rep."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109518_b0095","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.3390\/ijms26073102","article-title":"The art of PEGylation: from simple polymer to sophisticated drug delivery system","volume":"26","author":"Makharadze","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","article-title":"PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy","volume":"24","author":"Kesharwani","year":"2025","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0105","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Tt","year":"2020","journal-title":"Polymers"},{"key":"10.1016\/j.lungcan.2026.109518_b0110","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304713","article-title":"Charge-reversible nanoparticles: advanced delivery systems for therapy and diagnosis","volume":"20","author":"Veider","year":"2024","journal-title":"Small"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109518_b0115","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/bioengineering10070760","article-title":"Recent advances in nanomaterials-based targeted drug delivery for preclinical cancer diagnosis and therapeutics","volume":"10","author":"Tiwari","year":"2023","journal-title":"Bioengineering"},{"key":"10.1016\/j.lungcan.2026.109518_b0120","article-title":"Advances in targeted therapy for tumor with nanocarriers: a review","volume":"31","author":"Cheng","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","article-title":"The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents","volume":"37","author":"Siemann","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2026.109518_b0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for cancer therapy: current progress and challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.lungcan.2026.109518_b0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12951-021-01232-5","article-title":"The bright future of nanotechnology in lymphatic system imaging and imaging-guided surgery","volume":"20","author":"Qi","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109518_b0140","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1021\/acsabm.0c00515","article-title":"Noninvasive preclinical evaluation of targeted nanoparticles for the delivery of curcumin in treating pancreatic cancer","volume":"3","author":"Prabhuraj","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.lungcan.2026.109518_b0145","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","author":"Attia","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109518_b0150","doi-asserted-by":"crossref","first-page":"11015","DOI":"10.2147\/IJN.S549893","article-title":"Nanotechnology for neurodegenerative diseases: recent progress in brain-targeted delivery, stimuli-responsive platforms, and organelle-specific therapeutics","volume":"20","author":"Gao","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"15","key":"10.1016\/j.lungcan.2026.109518_b0155","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.3390\/ijms25158553","article-title":"EGFR- and Integrin \u03b1V\u03b23-targeting peptides as potential radiometal-labeled radiopharmaceuticals for cancer theranostics","volume":"25","author":"Toledo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109518_b0160","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/jfb14090466","article-title":"Targeted EGFR nanotherapy in non-small cell lung cancer","volume":"14","author":"Crintea","year":"2023","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.lungcan.2026.109518_b0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ddr.21545","article-title":"Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems","volume":"80","author":"Narmani","year":"2019","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.lungcan.2026.109518_b0170","doi-asserted-by":"crossref","DOI":"10.37349\/eds.2025.1008126","article-title":"Challenges in drug delivery to the tumors\u2014nanoparticles in medicine","volume":"3","author":"Bartusik-Aebisher","year":"2025","journal-title":"Explor. Drug Sci."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109518_b0175","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/pharmaceutics15092233","article-title":"Recent advances in targeted drug delivery strategy for enhancing oncotherapy","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0180","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3390\/pharmaceutics16121584","article-title":"Nanomedicines for pulmonary drug delivery: overcoming barriers in the treatment of respiratory infections and lung cancer","volume":"16","author":"Fern\u00e1ndez-Garc\u00eda","year":"2024","journal-title":"Pharmaceutics"},{"issue":"Part 4","key":"10.1016\/j.lungcan.2026.109518_b0185","article-title":"A review on biomacromolecular ligand-directed nanoparticles: new era in macrophage targeting","volume":"306","author":"Swami","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0190","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4254\/wjh.v16.i4.566","article-title":"Molecular mechanism of nanomaterials induced liver injury: a review","volume":"16","author":"Das","year":"2024","journal-title":"World J. Hepatol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0195","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/nano10020183","article-title":"Multifunctional nanocarriers for lung drug delivery","volume":"10","author":"Pontes","year":"2020","journal-title":"Nanomaterials"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/ph11010028","article-title":"Low molecular weight chitosan-coated PLGA nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis","volume":"11","author":"Al-Nemrawi","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0205","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3390\/pharmaceutics13122045","article-title":"Polymeric nanoparticles properties and brain delivery","volume":"13","author":"Ribovski","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lungcan.2026.109518_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117357","article-title":"Inorganic nanoparticles and blood-brain barrier modulation: advancing targeted neurological therapies","volume":"287","author":"Razavi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lungcan.2026.109518_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116627","article-title":"Engineering the protein corona: strategies, effects, and future directions in nanoparticle therapeutics","volume":"175","author":"Zhao","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/pharmaceutics18010066","article-title":"From circulation to regeneration: blood cell membrane-coated nanoparticles as drug delivery platform for immune-regenerative therapy","volume":"18","author":"Kim","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lungcan.2026.109518_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202400153","article-title":"Preclinical development of a genetically engineered albumin-binding nanoparticle of paclitaxel","volume":"4","author":"Saha","year":"2024","journal-title":"Small Sci."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109518_b0230","first-page":"3445","article-title":"Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator","volume":"11","author":"Chen","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109518_b0235","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijrobp.2013.02.009","article-title":"Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer","volume":"86","author":"Werner","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2026.109518_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189547","article-title":"Organic nanoplatforms for metallodrugs delivery: current advances in colorectal cancer","volume":"1881","author":"Neto","year":"2026","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0245","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1080\/10717544.2017.1410256","article-title":"Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy","volume":"24","author":"Qi","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lungcan.2026.109518_b0250","doi-asserted-by":"crossref","first-page":"13255","DOI":"10.2147\/IJN.S551752","article-title":"Key nano-strategies for cisplatin resistance in advancing anti-cancer therapy","volume":"20","author":"Lei","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0255","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/17435889.2026.2615102","article-title":"Designing drug delivery systems: the impact of structural order and disorder for optimized therapeutic outcomes","volume":"21","author":"Masoero","year":"2026","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0260","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12088-024-01298-3","article-title":"Lipidic nanosystem as state-of-the-art nanovehicle for biomedical applications","volume":"64","author":"Otavi","year":"2024","journal-title":"Indian J. Microbiol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109518_b0265","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/nano15171326","article-title":"Lipid-based drug delivery systems: concepts and recent advances in transdermal applications","volume":"15","author":"Antonara","year":"2025","journal-title":"Nanomaterials"},{"key":"10.1016\/j.lungcan.2026.109518_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202100639","article-title":"Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization","volume":"11","author":"van der Koog","year":"2022","journal-title":"Adv. Healthc. Mater."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0275","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3390\/pharmaceutics16121525","article-title":"Innovative approaches to enhancing the biomedical properties of liposomes","volume":"16","author":"Dejeu","year":"2024","journal-title":"Pharmaceutics"},{"issue":"25","key":"10.1016\/j.lungcan.2026.109518_b0290","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.2174\/0109298673308951240921121345","article-title":"Liposomal nanoformulation-encapsulated paclitaxel for reducing chemotherapy side effects in lung cancer treatments: recent advances and future outlooks","volume":"32","author":"Mohammad-Jafari","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lungcan.2026.109518_b0295","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.2147\/IJN.S450534","article-title":"EGFR targeting of liposomal doxorubicin improves recognition and suppression of non-small cell lung cancer","volume":"19","author":"Moles","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109518_b0300","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00432-022-04079-x","article-title":"Liposomal formulations for lung cancer treatment in the last two decades: a systematic review","volume":"148","author":"Can\u00e3o","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109518_b0305","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.3390\/ijms25179337","article-title":"Liposomal formulations of metallodrugs for cancer therapy","volume":"25","author":"Botter","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109518_b0310","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/CAD.0b013e32833d9adf","article-title":"Liposomal cisplatin: a new cisplatin formulation","volume":"21","author":"Stathopoulos","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109518_b0315","doi-asserted-by":"crossref","first-page":"34824","DOI":"10.18632\/oncotarget.9189","article-title":"Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: a meta-analysis of randomized controlled trials","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2026.109518_b0320","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/IJN.S53310","article-title":"GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation","volume":"9","author":"Cheng","year":"2014","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0325","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/10717544.2018.1425777","article-title":"Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide","volume":"25","author":"Lin","year":"2018","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0330","first-page":"1513","article-title":"L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review","volume":"6","author":"Xia","year":"2014","journal-title":"J. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0335","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/jnt5040012","article-title":"Characteristics and preparation of solid lipid nanoparticles and nanostructured lipid carriers","volume":"5","author":"Queiroz","year":"2024","journal-title":"J. Nanotheranostics"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109518_b0340","doi-asserted-by":"crossref","first-page":"15764","DOI":"10.3390\/ijms242115764","article-title":"Lipid nanoparticles: an effective tool to improve the bioavailability of nutraceuticals","volume":"24","author":"Ashfaq","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2026.109518_b0345","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.2147\/IJN.S539908","article-title":"Advances in targeted engineered nanoparticle-based therapeutics for respiratory diseases: current insights and future perspectives","volume":"20","author":"Chai","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0350","doi-asserted-by":"crossref","DOI":"10.1002\/biot.70147","article-title":"Application of nano-drug delivery systems in lung cancer diagnosis and treatment","volume":"20","author":"Tian","year":"2025","journal-title":"Biotechnol. J."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0355","first-page":"26","article-title":"Advances in nanotechnology-based delivery systems for EGFR tyrosine kinase inhibitors in cancer therapy","volume":"15","author":"Zhou","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109518_b0360","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.3390\/molecules25163731","article-title":"Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology","volume":"25","author":"Zieli\u0144ska","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0365","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/ddc2040045","article-title":"Nanoscale self-assemblies from amphiphilic block copolymers as proficient templates in drug delivery","volume":"2","author":"Patel","year":"2023","journal-title":"Drugs Drug Candidates"},{"key":"10.1016\/j.lungcan.2026.109518_b0370","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/374252","article-title":"Stealth properties to improve therapeutic efficacy of drug nanocarriers","volume":"2013","author":"Salmaso","year":"2013","journal-title":"J. Drug Delivery"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0375","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","article-title":"Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"18","author":"Kim","year":"2007","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0380","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.4143\/crt.2022.1436","article-title":"Safety and tolerability of weekly Genexol-PM, a Cremophor-free polymeric micelle formulation of paclitaxel, with carboplatin in gynecologic cancer: a phase I study","volume":"55","author":"Nam","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0385","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-014-2498-5","article-title":"A phase II trial of Cremophor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer","volume":"74","author":"Ahn","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109518_b0390","series-title":"Nanomedicine: Nanotechnology Biology and Medicine","first-page":"189","article-title":"Phase I\/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer","author":"Sanoff","year":"2019"},{"key":"10.1016\/j.lungcan.2026.109518_b0400","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.actbio.2021.02.001","article-title":"Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models","volume":"124","author":"Zhang","year":"2021","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0405","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/pharmaceutics18010130","article-title":"Albumin nanoparticles as multifunctional carriers for advanced therapeutics","volume":"18","author":"Konopska","year":"2026","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0410","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3390\/pharmaceutics16101322","article-title":"Serum albumin in nasal drug delivery systems: exploring the role and application","volume":"16","author":"Mardikasari","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lungcan.2026.109518_b0415","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2025.01.035","article-title":"Albumin-based delivery systems: recent advances, challenges, and opportunities","volume":"380","author":"Murphy","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lungcan.2026.109518_b0420","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1139248","article-title":"Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis","volume":"10","author":"Tan","year":"2023","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109518_b0425","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf189","article-title":"Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer","volume":"30","author":"Sun","year":"2025","journal-title":"The Oncologist"},{"issue":"20","key":"10.1016\/j.lungcan.2026.109518_b0430","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.3390\/ijms222010952","article-title":"Biocompatibility and cytotoxicity of gold nanoparticles: recent advances in methodologies and regulations","volume":"22","author":"Kus-Li\u015bkiewicz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109518_b0435","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.3390\/molecules18055858","article-title":"Gold nanoparticle contrast agents in advanced X-ray imaging technologies","volume":"18","author":"Ahn","year":"2013","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109518_b0440","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.3390\/molecules29112438","article-title":"Application of High-Z nanoparticles to enhance current radiotherapy treatment","volume":"29","author":"Jackson","year":"2024","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101210","article-title":"Radiosensitizing effect of gold nanoparticle loaded with small interfering RNA-SP1 on lung cancer: AuNPs-si-SP1 regulates GZMB for radiosensitivity","volume":"14","author":"Zhuang","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.lungcan.2026.109518_b0450","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202504285","article-title":"Dual-peptide nanoplatform: mesoporous silica nanoparticles functionalized with a cell-penetrating peptide and loaded with rationally designed antimicrobial peptides for tuberculosis therapy","author":"Carnero Canales","year":"2026","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0455","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1038\/s41598-025-90714-9","article-title":"PI3K\u03b1-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells","volume":"15","author":"Thibault","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109518_b0460","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41392-023-01654-7","article-title":"Multifunctional mesoporous silica nanoparticles for biomedical applications","volume":"8","author":"Xu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"22","key":"10.1016\/j.lungcan.2026.109518_b0465","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.3390\/ijms262210842","article-title":"Sub-15 nm nanoparticles for drug delivery: emerging frontiers and therapeutic potential","volume":"26","author":"De","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2026.109518_b0470","article-title":"Exploiting recent trends for the synthesis and surface functionalization of mesoporous silica nanoparticles towards biomedical applications","volume":"4","author":"Siddiqui","year":"2022","journal-title":"Int. J. Pharm.: X"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109518_b0475","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.3390\/polym14235249","article-title":"Recent advances in stimuli-responsive doxorubicin delivery systems for liver cancer therapy","volume":"14","author":"Radu","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.lungcan.2026.109518_b0480","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/578290","article-title":"Carbon nanotubes: applications in pharmacy and medicine","volume":"2013","author":"He","year":"2013","journal-title":"Biomed Res. Int."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109518_b0485","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/s23063230","article-title":"Modern electrochemical biosensing based on nucleic acids and carbon nanomaterials","volume":"23","author":"Szymczyk","year":"2023","journal-title":"Sensors"},{"issue":"16","key":"10.1016\/j.lungcan.2026.109518_b0490","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1039\/D4NA00278D","article-title":"Carbon nanomaterials as carriers for the anti-cancer drug doxorubicin: a review on theoretical and experimental studies","volume":"6","author":"Gayathri","year":"2024","journal-title":"Nanoscale Adv."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109518_b0495","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1002\/pol.20230820","volume":"62","author":"Gu","year":"2024","journal-title":"J. Polymer Science"},{"issue":"17","key":"10.1016\/j.lungcan.2026.109518_b0500","doi-asserted-by":"crossref","first-page":"11025","DOI":"10.1021\/acsnano.3c08335","article-title":"Superparamagnetic iron oxide nanoparticles reprogram the tumor microenvironment and reduce lung cancer regrowth after crizotinib treatment","volume":"18","author":"Horvat","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.lungcan.2026.109518_b0280","doi-asserted-by":"crossref","first-page":"12485","DOI":"10.2147\/IJN.S538382","article-title":"Liposome-based nanoparticle delivery systems for lung diseases: opportunities and challenges","volume":"20","author":"Zhang","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s11671-024-04170-x","article-title":"The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases","volume":"20","author":"Okafor","year":"2025","journal-title":"Discover Nano"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109518_b0395","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3390\/pharmaceutics14112432","article-title":"Advancements in polymeric nanocarriers to mediate targeted therapy against triple-negative breast cancer","volume":"14","author":"Fatima","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0505","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/medicina60040653","article-title":"Health effects of ionizing radiation on the human body","volume":"60","author":"Talapko","year":"2024","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0510","first-page":"176","article-title":"Genomic and proteomic biomarkers for cancer: a multitude of opportunities","volume":"1796","author":"Tainsky","year":"2009","journal-title":"BBA"},{"issue":"15","key":"10.1016\/j.lungcan.2026.109518_b0515","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/cancers15153837","article-title":"Precision medicine: disease subtyping and tailored treatment","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.lungcan.2026.109518_b0520","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.3390\/molecules30153177","article-title":"Nano-phytomedicine: harnessing plant-derived phytochemicals in nanocarriers for targeted human health applications","volume":"30","author":"Parvin","year":"2025","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0525","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/genes14101906","article-title":"Prognostic factors and markers in non-small cell lung cancer: recent progress and future challenges","volume":"14","author":"Meira","year":"2023","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109518_b0530","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/cells7110212","article-title":"Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy","volume":"7","author":"Nagano","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.lungcan.2026.109518_b0535","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.actbio.2021.05.018","article-title":"Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer","volume":"129","author":"Chen","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.lungcan.2026.109518_b0540","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40364-024-00686-7","article-title":"New strategies for lung cancer diagnosis and treatment: applications and advances in nanotechnology","volume":"12","author":"Feng","year":"2024","journal-title":"Biomarker Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109518_b0545","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s44446-025-00046-y","article-title":"Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges","volume":"33","author":"Sakkal","year":"2025","journal-title":"Saudi Pharm. J."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0550","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.21037\/tcr-23-956","article-title":"Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0555","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13402-025-01152-8","article-title":"A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC","volume":"49","author":"Wang","year":"2026","journal-title":"Cell Oncology"},{"key":"10.1016\/j.lungcan.2026.109518_b0560","article-title":"Multifunctional nanoplatforms for tumor microenvironment remodeling: toward precision and intelligent cancer therapy","volume":"35","author":"Deng","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0565","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1049\/iet-nbt.2017.0128","article-title":"Nano-biosensor based on reduced graphene oxide and gold nanoparticles, for detection of phenylketonuria-associated DNA mutation","volume":"12","author":"Seifati","year":"2018","journal-title":"IET Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0570","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s11671-018-2565-7","article-title":"Enhanced plasmonic biosensors of hybrid gold nanoparticle-graphene oxide-based label-free immunoassay","volume":"13","author":"Chiu","year":"2018","journal-title":"Nanoscale Res. Lett."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0575","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-24-1417","article-title":"EML4\u2212ALK variant-specific genetic interactions shape lung tumorigenesis","volume":"16","author":"Diaz-Jimenez","year":"2026","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0580","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.7150\/thno.24469","article-title":"Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system","volume":"8","author":"Li","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.10.045","article-title":"MET receptor tyrosine kinase as a therapeutic anticancer target","volume":"280","author":"Stellrecht","year":"2009","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0590","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-022-01681-y","article-title":"Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC","volume":"21","author":"Sun","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lungcan.2026.109518_b0595","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12935-024-03558-0","article-title":"Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy","volume":"24","author":"Mengistu","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0600","first-page":"264","article-title":"Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer","volume":"4","author":"Benko","year":"2021","journal-title":"Cancer Drug Resistance"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109518_b0605","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/ph16030349","article-title":"Functionalized lipid nanocarriers for simultaneous delivery of docetaxel and tariquidar to chemoresistant cancer cells","volume":"16","author":"Kim","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0610","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3390\/ph18121828","article-title":"Enhanced anti-tumor efficacy of paclitaxel nanoparticles via supramolecular self-assembly with pterostilbene","volume":"18","author":"Liang","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lungcan.2026.109518_b0615","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/DTI.S12519","article-title":"P-glycoprotein inhibition for optimal drug delivery","volume":"7","author":"Amin","year":"2013","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.lungcan.2026.109518_b0620","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.2147\/DDDT.S172199","article-title":"Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109518_b0625","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/polym17081010","article-title":"Development of stimuli-responsive polymeric nanomedicines in hypoxic tumors and their therapeutic promise in oral cancer","volume":"17","author":"Hou","year":"2025","journal-title":"Polymers"},{"key":"10.1016\/j.lungcan.2026.109518_b0630","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.2147\/DDDT.S260253","article-title":"Synergistic combination chemotherapy of lung cancer: cisplatin and doxorubicin conjugated prodrug loaded, glutathione and pH sensitive nanocarriers","volume":"14","author":"Jin","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lungcan.2026.109518_b0635","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-023-01768-8","article-title":"Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugs","volume":"21","author":"Park","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109518_b0640","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s13346-020-00867-5","article-title":"Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer","volume":"11","author":"Patel","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0645","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11912-023-01492-4","article-title":"Integrative oncology approaches to supporting immune checkpoint inhibitor treatment of solid tumours","volume":"26","author":"Fuller-Shavel","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.lungcan.2026.109518_b0650","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251338390","article-title":"Drug delivery system for cancer immunotherapy: potential roles, challenge and recent advances","volume":"24","author":"Lin","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2026.109518_b0655","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0660","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/pharmaceutics14040866","article-title":"Emerging nanotherapeutic approaches to overcome drug resistance in cancers with update on clinical trials","volume":"14","author":"Bukhari","year":"2022","journal-title":"Pharmaceutics"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109518_b0665","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi2046","article-title":"Antibody nanoparticle conjugate-based targeted immunotherapy for non-small cell lung cancer","volume":"10","author":"Saha","year":"2024","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0670","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003464","article-title":"Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity","volume":"9","author":"Chen","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109518_b0675","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1618903","article-title":"Research advances in immune agonists and their nanoparticles for enhancing the immunotherapeutic efficacy of PD-1 inhibitors in malignancies","volume":"15","author":"Xia","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109518_b0680","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.201900076","article-title":"Nanoparticles-mediated combination therapies for cancer treatment","volume":"2","author":"Shrestha","year":"2019","journal-title":"Adv. Therap."},{"key":"10.1016\/j.lungcan.2026.109518_b0685","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.2147\/DDDT.S544567","article-title":"Prospects and challenges of chitosan-based drug carriers for anticancer agents\u2019 delivery against lung cancer: a review","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lungcan.2026.109518_b0690","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.lungcan.2026.109518_b0695","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40820-025-01862-6","article-title":"Synergistic ferroptosis\u2013immunotherapy nanoplatforms: multidimensional engineering for tumor microenvironment remodeling and therapeutic optimization","volume":"18","author":"Wei","year":"2026","journal-title":"Nano-Micro Letters"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0700","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000526899","article-title":"PD-1\/CTLA-4 blockade leads to expansion of CD8+PD-1^int^TILs and results in tumor remission in experimental liver cancer","volume":"12","author":"Bufe","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.lungcan.2026.109518_b0705","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1038\/s41467-023-42972-2","article-title":"Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy","volume":"14","author":"Guo","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109518_b0710","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3390\/pharmaceutics17101301","article-title":"Application of biomimetic SPIONs in targeted lung cancer therapy: cell-membrane camouflage technology and lung retention enhancement strategies","volume":"17","author":"Liu","year":"2025","journal-title":"Pharmaceutics"},{"issue":"16","key":"10.1016\/j.lungcan.2026.109518_b0715","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.7150\/ijms.120868","article-title":"Advances in tumor antigen vaccines: a new frontier in cancer immunotherapy","volume":"22","author":"Feng","year":"2025","journal-title":"Int. J. Med. Sci."},{"issue":"27","key":"10.1016\/j.lungcan.2026.109518_b0720","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1200\/JCO.2005.13.011","article-title":"Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer","volume":"23","author":"Butts","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0725","first-page":"161","article-title":"Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches","volume":"2","author":"Grasso","year":"2010","journal-title":"Int. J. Physiol. Pathophys. Pharmacol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109518_b0730","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00002371-200109000-00004","article-title":"Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response","volume":"24","author":"Nguyen","year":"2001","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109518_b0735","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/anie.201804882","article-title":"Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy","volume":"58","author":"Duan","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109518_b0740","doi-asserted-by":"crossref","first-page":"8382","DOI":"10.7150\/thno.45391","article-title":"Nanomicelle protects the immune activation effects of paclitaxel and sensitizes tumors to anti-PD-1 immunotherapy","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0745","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12885-019-6499-y","article-title":"Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells","volume":"20","author":"Yoshida","year":"2020","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109518_b0750","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1039\/D1BM00112D","article-title":"Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy","volume":"9","author":"Wang","year":"2021","journal-title":"Biomater. Sci."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109518_b0755","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1208\/s12248-018-0267-9","article-title":"Nanoparticle-based delivery of CRISPR\/Cas9 genome-editing therapeutics","volume":"20","author":"Givens","year":"2018","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0760","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41392-020-00283-8","article-title":"The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer","volume":"5","author":"He","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109518_b0765","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.3390\/ijms251810166","article-title":"Development of mRNA lipid nanoparticles: targeting and therapeutic aspects","volume":"25","author":"Liu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0770","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12951-025-04019-0","article-title":"Lung-targeted RNA delivery systems: strategies and therapeutic applications","volume":"24","author":"Xu","year":"2026","journal-title":"J. Nanobiotechnol."},{"issue":"29","key":"10.1016\/j.lungcan.2026.109518_b0775","article-title":"Tumor-tailored ionizable lipid nanoparticles facilitate IL-12 circular RNA delivery for enhanced lung cancer immunotherapy","volume":"36","author":"Xu","year":"2024","journal-title":"Adv. Mater."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109518_b0780","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/pharmaceutics16091228","article-title":"Nanotechnology in advancing chimeric antigen receptor T cell therapy for cancer treatment","volume":"16","author":"Kang","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109518_b0785","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7150\/thno.8698","article-title":"Nanotheranostics\u2014application and further development of nanomedicine strategies for advanced theranostics","volume":"4","author":"Muthu","year":"2014","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109518_b0790","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1586\/erm.13.15","article-title":"Nanotheranostics for personalized medicine","volume":"13","author":"Kim","year":"2013","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.lungcan.2026.109518_b0795","doi-asserted-by":"crossref","first-page":"14343","DOI":"10.2147\/IJN.S557784","article-title":"Actively targeted nanoparticles for enhanced diagnosis, treatment, and vaccination of tuberculosis: a systematic review","volume":"20","author":"Cung","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"Part 1","key":"10.1016\/j.lungcan.2026.109518_b0800","article-title":"Sensitive electrochemical immunosensor for CYFRA21-1 detection based on AuNPs@MoS2@TiC2Tx composites","volume":"238","author":"Hu","year":"2022","journal-title":"Talanta"},{"key":"10.1016\/j.lungcan.2026.109518_b0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-025-03988-6","article-title":"Covalent organic framework-based electrochemical nanosensing: an emerging paradigm for early cancer diagnosis and longitudinal surveillance","volume":"24","author":"Zhang","year":"2026","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.lungcan.2026.109518_b0810","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12668-025-02331-5","article-title":"Advances on gold nanoparticle-based biosensors for detection of SARS-CoV-2","volume":"16","author":"Naik","year":"2026","journal-title":"BioNanoScience"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0815","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/bios15040199","article-title":"Innovative applications of nanopore technology in tumor screening: an exosome-centric approach","volume":"15","author":"Chi","year":"2025","journal-title":"Biosensors"},{"key":"10.1016\/j.lungcan.2026.109518_b0820","article-title":"Nanomaterials assisted exosomes isolation and analysis towards liquid biopsy","volume":"16","author":"Fang","year":"2022","journal-title":"Mater. Today Bio"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109518_b0825","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/bios16020104","article-title":"Recent advances in microfluidic chip technology for laboratory medicine: innovations and artificial intelligence integration","volume":"16","author":"Cai","year":"2026","journal-title":"Biosensors"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0830","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202307360","article-title":"AuNPs\/CNC nanocomposite with a \u201cdual dispersion\u201d effect for LDI-TOF MS analysis of intact proteins in NSCLC serum exosomes","volume":"11","author":"Shan","year":"2024","journal-title":"Adv. Sci."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109518_b0835","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.13976","article-title":"Advancements in ion mobility-based diagnostics for infectious diseases","volume":"25","author":"Kartowikromo","year":"2025","journal-title":"Proteomics"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109518_b0840","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.3390\/molecules25246049","article-title":"Methotrexate gold nanocarriers: loading and release study: its activity in colon and lung cancer cells","volume":"25","author":"\u00c1lvarez-Gonz\u00e1lez","year":"2020","journal-title":"Molecules"},{"issue":"20","key":"10.1016\/j.lungcan.2026.109518_b0845","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.3390\/nano12203686","article-title":"SPIONs conjugate supported anticancer drug doxorubicin's delivery: current status, challenges, and prospects","volume":"12","author":"Akhtar","year":"2022","journal-title":"Nanomaterials"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0850","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2217\/nnm.12.160","article-title":"EGF receptor-targeted nanocarriers for enhanced cancer treatment","volume":"7","author":"Master","year":"2012","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0855","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3988\/jcn.2025.0563","article-title":"From ablation to neuromodulation platform: the evolving role of magnetic resonance-guided focused ultrasound in functional neurosurgery","volume":"22","author":"Lee","year":"2026","journal-title":"J. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0860","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/cbic.200700509","article-title":"Multifunctional mesoporous silica nanoparticles for intracellular labeling and animal magnetic resonance imaging studies","volume":"9","author":"Wu","year":"2008","journal-title":"Chembiochem"},{"key":"10.1016\/j.lungcan.2026.109518_b0865","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3762\/bjnano.12.24","article-title":"Doxorubicin-loaded gold nanorods: a multifunctional chemo-photothermal nanoplatform for cancer management","volume":"12","author":"Awan","year":"2021","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.lungcan.2026.109518_b0870","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2147\/IJN.S157082","article-title":"The theranostic efficiency of tumor-specific, pH-responsive, peptide-modified, liposome-containing paclitaxel and superparamagnetic iron oxide nanoparticles","volume":"13","author":"Zheng","year":"2018","journal-title":"Int. J. Nanomed."},{"issue":"19","key":"10.1016\/j.lungcan.2026.109518_b0875","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"RESILIENT trial investigators, RESILIENT part 2: a randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109518_b0880","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/cancers11050597","article-title":"Recent progress in the theranostics application of nanomedicine in lung cancer","volume":"11","author":"Mukherjee","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0885","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/diagnostics12040851","article-title":"First-in-human study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin \u03b1v\u03b23 imaging in patients with breast cancer and neuroendocrine neoplasms: safety, dosimetry and tumor imaging ability","volume":"12","author":"Clausen","year":"2022","journal-title":"Diagnostics"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109518_b0890","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/genes14071370","article-title":"Potential applications of nanoparticles in improving the outcome of lung cancer treatment","volume":"14","author":"Girigoswami","year":"2023","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0895","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-023-01463-z","article-title":"Advances of medical nanorobots for future cancer treatments","volume":"16","author":"Kong","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109518_b0900","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.drudis.2020.03.005","article-title":"DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns","volume":"25","author":"Zheng","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lungcan.2026.109518_b0905","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nbt.4071","article-title":"A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo","volume":"36","author":"Li","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lungcan.2026.109518_b0910","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2147\/OTT.S550104","article-title":"Precision nanomedicine for cancer: innovations, strategies, and translational challenges","volume":"18","author":"Wen","year":"2025","journal-title":"Onco Targets Therapy"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0915","first-page":"1010","article-title":"Enhanced permeability and retention (EPR) effect based tumor targeting: the concept, application and prospect","volume":"2","author":"Yin","year":"2014","journal-title":"JSM Clin. Oncol. Res."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109518_b0920","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3390\/cancers14122868","article-title":"An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment","volume":"14","author":"Sharifi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109518_b0925","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2015.08.017","article-title":"Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors","volume":"219","author":"Miao","year":"2015","journal-title":"J. Control. Release"},{"issue":"22","key":"10.1016\/j.lungcan.2026.109518_b0930","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319880121","article-title":"Curvature-mediated rapid extravasation and penetration of nanoparticles against interstitial fluid pressure for improved drug delivery","volume":"121","author":"Jiang","year":"2024","journal-title":"PNAS"},{"issue":"20","key":"10.1016\/j.lungcan.2026.109518_b0935","doi-asserted-by":"crossref","first-page":"19810","DOI":"10.1021\/acsnano.3c04037","article-title":"Meta-analysis of nanoparticle distribution in tumors and major organs in tumor-bearing mice","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"issue":"35","key":"10.1016\/j.lungcan.2026.109518_b0940","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.2174\/0929867325666180601101859","article-title":"Coating matters: review on colloidal stability of nanoparticles with biocompatible coatings in biological media, living cells and organisms","volume":"25","author":"Schubert","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lungcan.2026.109518_b0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103046","article-title":"Impact of protein coronas on nanoparticle interactions with tissues and targeted delivery","volume":"85","author":"Chou","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.lungcan.2026.109518_b0950","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/s41467-026-70453-9","article-title":"Surface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis","volume":"17","author":"Wu","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109518_b0955","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9954443","article-title":"Toxicity of nanoparticles in biomedical application: nanotoxicology","volume":"2021","author":"Egbuna","year":"2021","journal-title":"J. Toxicol."},{"key":"10.1016\/j.lungcan.2026.109518_b0960","first-page":"1117","article-title":"Nanotoxicology and nanoparticle safety in biomedical designs","volume":"6","author":"Ai","year":"2011","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109518_b0965","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1039\/C8NR07769J","article-title":"Applications of nanoparticles in biomedical imaging","volume":"11","author":"Han","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.lungcan.2026.109518_b0970","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2021.04.016","article-title":"Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions","volume":"334","author":"Huang","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0975","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12951-025-03371-5","article-title":"The nano-paradox: addressing nanotoxicity for sustainable agriculture, circular economy and SDGs","volume":"23","author":"Rajpal","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.lungcan.2026.109518_b0980","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20220045","volume":"3","author":"Lu","year":"2023","journal-title":"Exploration"},{"key":"10.1016\/j.lungcan.2026.109518_b0985","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b0990","first-page":"1","article-title":"Nanoparticle-induced oxidative stress: mechanisms and implications for human health and environmental safety","volume":"37","author":"Neogi","year":"2025","journal-title":"Environ. Earth Sci. Proc."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109518_b0995","doi-asserted-by":"crossref","first-page":"383","DOI":"10.21147\/j.issn.1000-9604.2016.04.01","article-title":"Overproduction of reactive oxygen species\u2014obligatory or not for induction of apoptosis by anticancer drugs","volume":"28","author":"Ivanova","year":"2016","journal-title":"Chin. J. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109518_b1000","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s00204-017-1993-y","article-title":"Toxicology of silica nanoparticles: an update","volume":"91","author":"Murugadoss","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.lungcan.2026.109518_b1005","volume":"31","author":"Yan","year":"2019","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b1010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/pharmaceutics18010011","article-title":"A systematic review of advanced drug delivery systems: engineering strategies, barrier penetration, and clinical progress (2016\u2013April 2025)","volume":"18","author":"Uzakova","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lungcan.2026.109518_b1015","doi-asserted-by":"crossref","first-page":"15185","DOI":"10.2147\/IJN.S568952","article-title":"Self-assembled nanoparticles: overcoming limitations of conventional nanomedicines for enhanced tumor therapy","volume":"20","author":"Tang","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.lungcan.2026.109518_b1020","article-title":"Advances in nanoparticles as drug delivery systems: a review","volume":"30","author":"Akomolafe","year":"2025","journal-title":"Sci. Afr."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109518_b1025","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/foods14060973","article-title":"Lipid nanoparticles: formulation, production methods and characterization protocols","volume":"14","author":"L\u00fcdtke","year":"2025","journal-title":"Foods"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109518_b1030","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/cryst11030310","article-title":"Application of fundamental techniques for physicochemical characterizations to understand post-formulation performance of pharmaceutical nanocrystalline materials","volume":"11","author":"Witika","year":"2021","journal-title":"Crystals"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109518_b1035","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","article-title":"Current approaches of nanomedicines in the market and various stage of clinical translation","volume":"12","author":"Shan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109518_b1040","article-title":"Active learning in materials science with emphasis on adaptive sampling using uncertainties for targeted design","volume":"5","author":"Lookman","year":"2019","journal-title":"Npj Comp. Mater."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109518_b1045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41181-022-00168-x","article-title":"Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals","volume":"7","author":"Korde","year":"2022","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.lungcan.2026.109518_b1050","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2025.1686599","article-title":"Systematic review of nanoelectronic drug delivery systems advancing technological innovation, clinical integration, and personalized therapy","volume":"7","author":"Eze","year":"2026","journal-title":"Front. Nanotechnol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:26:47Z","timestamp":1791271607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":210,"alternative-id":["S0169500226005799"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109518","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticle-based drug delivery for precision lung cancer therapy: Tumor microenvironment modulation and theranostic applications","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109518"}}